Omicron infection-associated T- and B-cell immunity in antigen-naive and triple-COVID-19-vaccinated individuals

Front Immunol. 2023 May 5:14:1166589. doi: 10.3389/fimmu.2023.1166589. eCollection 2023.

Abstract

Since early 2022, various Omicron variants have dominated the SARS-CoV-2 pandemic in most countries. All Omicron variants are B-cell immune escape variants, and antibodies induced by first-generation COVID-19 vaccines or by infection with earlier SARS-CoV-2 variants largely fail to protect individuals from Omicron infection. In the present study, we investigated the effect of Omicron infections in triple-vaccinated and in antigen-naive individuals. We show that Omicron breakthrough infections occurring 2-3.5 months after the third vaccination restore B-cell and T-cell immune responses to levels similar to or higher than those measured 14 days after the third vaccination, including the induction of Omicron-neutralizing antibodies. Antibody responses in breakthrough infection derived mostly from cross-reacting B cells, initially induced by vaccination, whereas Omicron infections in antigen-naive individuals primarily generated B cells binding to the Omicron but not the Wuhan spike protein. Although antigen-naive individuals mounted considerable T-cell responses after infection, B-cell responses were low, and neutralizing antibodies were frequently below the limit of detection. In summary, the detection of Omicron-associated B-cell responses in primed and in antigen-naive individuals supports the application of Omicron-adapted COVID-19 vaccines, but calls into question their suitability if they also contain/encode antigens of the original Wuhan virus.

Keywords: COVID-19; Omicron infection; Omicron variants; SARS-CoV-2; breakthrough infection; heterologous vaccination.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Neutralizing
  • Breakthrough Infections
  • COVID-19 Vaccines
  • COVID-19*
  • Humans
  • SARS-CoV-2

Substances

  • COVID-19 Vaccines
  • Antibodies, Neutralizing

Supplementary concepts

  • SARS-CoV-2 variants

Grants and funding

This work was supported by the German Center for Infection Research TTU 01.938 (grant no. 80018019238 to GMNB and RF), and TTU 04.820 to GMNB; by the Deutsche Forschungsgemeinschaft, (DFG, German Research Foundation) Excellence Strategy EXC 2155 “RESIST” (Project ID39087428 to RF); by funds from the State of Lower Saxony (14-76103-184 CORONA-11/20 to RF); by funds from the BMBF Bundesministerium für Bildung und Forschung (NaFoUniMedCovid19 FKZ: 01KX2021; Projects B-FAST to RF) and Deutsche Forschungsgemeinschaft, Sonderforschungsbereiche SFB 900/3 (Projects B1, 158989968 to RF); by the German Center for Lung Research (grant no. 82DZL002B1 to RF) and by the European Regional Development Fund (Defeat Corona, ZW7-8515131 to GMNB and ZW7-85151373 to GMNB).